Drug Profile
Anti-CD19 chimeric antigen receptor T cell therapy - Immune cell
Alternative Names: ICAR19 CAR-T cells - Immune CellLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Immune Cell
- Developer Immune Cell; Weifang People's Hospital
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported B-cell lymphoma; Leukaemia
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for phase-I development in B-cell lymphoma(In adolescents, In children, In the elderly, In adults) in China (IV, Infusion)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Leukaemia(In adolescents, In children, In the elderly, In adults) in China (IV, Infusion)
- 01 Mar 2017 Phase-I clinical trials in B-cell lymphoma (In children, In adolescents, In adults, In the elderly) in China (IV) (NCT03383952)